Mocksville, North Carolina--(Newsfile Corp. - March 28, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction, today reported results for the fourth quarter ended December 31, 2023, and provided an update on recent business highlights.
Fourth quarter results and recent business activities included:
Said Larry Firestone, Chairman and CEO: "Our turnaround is progressing rapidly, after restructuring a significant portion of the business over the last 120 days as part of our mandate to produce stronger future financial results. Most importantly, cash use has declined rapidly, from a peak run rate of approximately $15 million a quarter last year to less than $4 million projected in the first quarter of 2024, with continued sequential improvement expected in each quarter throughout 2024 as we move further from prior period cash obligations.
"We now have two primary areas of focus, both directly pertaining to our tobacco market assets. In the short-term, we will evaluate and profitably grow our contract manufacturing business to cover our operating expenses and mission critical initiatives around 22nd Century's very low nicotine content cigarette technology. We will also invest in and grow the VLN® brand through sales, customer awareness and capitalizing on a positive regulatory and social environment. With success in these efforts, we believe that 22nd Century can break even by the first quarter 2025.
"With VLN® being the only FDA authorized reduced nicotine content combustible cigarette in the industry, market awareness of the positive impact that a low nicotine cigarette has on adult smokers is the key to our success. VLN® is currently available in 5,100 stores across the country, and we will be adding distribution as we continue to drive brand awareness for this important new category in the fight to reduce the harms of smoking."
Recent Business Highlights
Corporate Updates
Fourth Quarter 2023 Financial Results
All figures reported below reflect continuing operations, excluding discontinued operations related to the sale of its hemp/cannabis franchise.
Reverse Stock Split
The Company announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.00001 per share (the "Common Stock"), at a ratio of 1-for-16. The reverse split will be effective at market open on Tuesday, April 2, 2024. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on Nasdaq.
Balance Sheet and Liquidity
As of December 31, 2023, the Company held $2.1 million in cash and cash equivalents. The Company has subsequently secured an additional $2.3 million in gross proceeds through the previously announced warrant exchange program plus additional proceeds through the sale of excess inventory and raw materials. Long-term debt declined to $8.1 million at year end, and short-term debt was $5.8 million of which $3.0 million of assets have been pledged against current obligations.
Conference Call
22nd Century will host a live webcast today at 8:00 a.m. E.T. to discuss its fourth quarter 2023 financial results and business highlights. The live webcast will be accessible in the Events section on 22nd Century's Investor Relations website at https://ir.xxiicentury.com/events-and-presentations/default.aspx. An archived replay of the webcast will also be available shortly after the live event has concluded.
About 22nd Century Group, Inc.
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.
Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.
Learn more about VLN® at tryvln.com.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
214-597-8200
22nd CENTURY GROUP, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(amounts in thousands, except per-share data)
| December 31, | December 31, | |||||
| 2023 | 2022 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 2,058 | $ | 2,205 | ||
| Short-term investment securities | - | 18,193 | ||||
| Accounts receivable, net | 1,671 | 1,363 | ||||
| Inventories | 4,346 | 7,270 | ||||
| Insurance recoveries | 3,768 | - | ||||
| GVB promissory note | 2,000 | - | ||||
| Prepaid expenses and other current assets | 1,180 | 1,928 | ||||
| Current assets of discontinued operations held for sale | 1,254 | 13,646 | ||||
| Total current assets | 16,277 | 44,605 | ||||
| Property, plant and equipment, net | 3,393 | 3,692 | ||||
| Operating lease right-of-use assets, net | 1,894 | 943 | ||||
| Intangible assets, net | 5,924 | 7,212 | ||||
| Other assets | 15 | 3,417 | ||||
| Noncurrent assets of discontinued operations held for sale | - | 54,782 | ||||
| Total assets | $ | 27,503 | $ | 114,651 | ||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Notes and loans payable - current | $ | 543 | $ | 689 | ||
| Current portion of long-term debt | 5,848 | - | ||||
| Operating lease obligations | 231 | 252 | ||||
| Accounts payable | 4,445 | 2,051 | ||||
| Accrued expenses | 1,322 | 766 | ||||
| Accrued litigation | 3,768 | - | ||||
| Accrued payroll | 883 | 2,662 | ||||
| Accrued excise taxes and fees | 2,234 | 1,423 | ||||
| Deferred income | 726 | 688 | ||||
| Other current liabilities | 1,849 | 349 | ||||
| Current liabilities of discontinued operations held for sale | 3,185 | 4,138 | ||||
| Total current liabilities | 25,034 | 13,018 | ||||
| Long-term liabilities: | ||||||
| Operating lease obligations | 1,698 | 711 | ||||
| Long-term debt | 8,058 | - | ||||
| Other long-term liabilities | 1,123 | 344 | ||||
| Noncurrent liabilities of discontinued operations held for sale | - | 4,603 | ||||
| Total liabilities | 35,914 | 18,676 | ||||
| Shareholders' equity (deficit) | ||||||
| Preferred stock, $.00001 par value, 10,000,000 shares authorized | ||||||
| Common stock, $.00001 par value, 66,666,667 shares authorized | ||||||
| Capital stock issued and outstanding: | ||||||
| 43,525,862 common shares (14,349,275 at December 31, 2022) | ||||||
| Common stock, par value | - | - | ||||
| Capital in excess of par value | 370,297 | 333,900 | ||||
| Accumulated other comprehensive loss | - | (111 | ) | |||
| Accumulated deficit | (378,707 | ) | (237,814 | ) | ||
| Total shareholders' equity (deficit) | (8,410 | ) | 95,975 | |||
| Total liabilities and shareholders' equity (deficit) | $ | 27,503 | $ | 114,651 | ||
22nd CENTURY GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(amounts in thousands, except per-share data)
| Three Months Ended | Year Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Revenues, net | $ | 7,357 | $ | 9,951 | $ | 32,204 | $ | 40,501 | ||||
| Cost of goods sold | 15,186 | 9,995 | 40,900 | 38,654 | ||||||||
| Gross (loss) profit | (7,829 | ) | (44 | ) | (8,696 | ) | 1,847 | |||||
| Operating expenses: | ||||||||||||
| Sales, general and administrative | 4,005 | 9,331 | 31,064 | 32,231 | ||||||||
| Research and development | 493 | 1,169 | 2,644 | 3,578 | ||||||||
| Other operating expense (income), net | 1,905 | (328 | ) | 2,527 | (327 | ) | ||||||
| Total operating expenses | 6,403 | 10,172 | 36,235 | 35,482 | ||||||||
| Operating loss from continuing operations | (14,232 | ) | (10,216 | ) | (44,931 | ) | (33,635 | ) | ||||
| Other income (expense): | ||||||||||||
| Realized loss on Panacea investment | - | (748 | ) | - | (2,789 | ) | ||||||
| Other income (expense), net | (170 | ) | (223 | ) | 334 | (366 | ) | |||||
| Loss on transfer of promissory note | (895 | ) | - | (895 | ) | - | ||||||
| Interest income, net | 18 | 102 | 219 | 313 | ||||||||
| Interest expense | (6,788 | ) | (29 | ) | (9,366 | ) | (55 | ) | ||||
| Total other expense | (7,835 | ) | (898 | ) | (9,708 | ) | (2,897 | ) | ||||
| Loss from continuing operations before income taxes | (22,067 | ) | (11,114 | ) | (54,639 | ) | (36,532 | ) | ||||
| Provision (benefit) for income taxes | 1 | - | 47 | 21 | ||||||||
| Net loss from continuing operations | $ | (22,068 | ) | $ | (11,114 | ) | $ | (54,686 | ) | $ | (36,553 | ) |
| Discontinued operations: | ||||||||||||
| Loss from discontinued operations before income taxes | $ | (6,809 | ) | $ | (13,020 | ) | $ | (85,634 | ) | (23,703 | ) | |
| Provision (benefit) for income taxes | 455 | 2,148 | 455 | (455 | ) | |||||||
| Net loss from discontinued operations | $ | (7,264 | ) | $ | (15,168 | ) | $ | (86,089 | ) | $ | (23,248 | ) |
| Net loss | $ | (29,332 | ) | $ | (26,282 | ) | $ | (140,775 | ) | $ | (59,801 | ) |
| Deemed dividends | (9,061 | ) | - | (9,992 | ) | - | ||||||
| Net loss available to common shareholders | $ | (38,393 | ) | $ | (26,282 | ) | $ | (150,767 | ) | $ | (59,801 | ) |
| Basic and diluted loss per common share from continuing operations | $ | (0.66 | ) | $ | (0.77 | ) | $ | (2.64 | ) | $ | (2.84 | ) |
| Basic and diluted loss per common share from discontinued operations | $ | (0.22 | ) | $ | (1.06 | ) | $ | (4.16 | ) | $ | (1.81 | ) |
| Basic and diluted loss per common share from deemed dividends | $ | (0.27 | ) | $ | - | $ | (0.48 | ) | $ | - | ||
| Basic and diluted loss per common share | $ | (1.15 | ) | $ | (1.83 | ) | $ | (7.28 | ) | $ | (4.65 | ) |
| Weighted average common shares outstanding - basic and diluted | 33,470 | $ | 14,353 | 20,711 | 12,856 | |||||||
Reconciliations of Non-GAAP Measures
Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the quarter and year ended December 31, 2023 and 2022, including a reconciliation of these Non-GAAP measures for such periods.
| Quarter Ended | |||||||||
| December 31, | |||||||||
| Dollar Amounts in Thousands ($000's) | |||||||||
| (UNAUDITED) | |||||||||
| $ Change | |||||||||
| 2023 | 2022 | fav / (unfav) | |||||||
| Net loss from continuing operations | $ | (22,068 | ) | $ | (11,114 | ) | $ | (10,954 | ) |
| Interest (income)/expense, net | 6,769 | (73 | ) | 6,842 | |||||
| Provision (benefit) for income taxes | 1 | - | 1 | ||||||
| Amortization and depreciation | 370 | 384 | (14 | ) | |||||
| EBITDA | $ | (14,928 | ) | $ | (10,803 | ) | $ | (4,125 | ) |
| Adjustments: | |||||||||
| Restructuring and impairment | 1,871 | 35 | 1,836 | ||||||
| Inventory write-down | 7,927 | - | 7,927 | ||||||
| Acquisition and transaction costs | - | - | - | ||||||
| Loss on change of warrant liability | 175 | - | 175 | ||||||
| Loss on transfer of promissory note | 895 | - | - | ||||||
| Equity-based employee compensation expense | 860 | 868 | (8 | ) | |||||
| Adjusted EBITDA | $ | (3,200 | ) | $ | (9,900 | ) | $ | 6,700 | |
| Adjusted EBITDA loss per common share | (0.10 | ) | (0.69 | ) | 0.59 | ||||
| Weighted average common shares outstanding - basic and diluted | 33,470 | 14,353 | |||||||
Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA
| Year Ended | |||||||||
| December 31, | |||||||||
| Dollar Amounts in Thousands ($000's) | |||||||||
| (UNAUDITED) | |||||||||
| $ Change | |||||||||
| 2023 | 2022 | fav / (unfav) | |||||||
| Net loss from continuing operations | $ | (54,686 | ) | $ | (36,553 | ) | $ | (18,133 | ) |
| Interest (income)/expense, net | 9,147 | (258 | ) | 9,405 | |||||
| Provision (benefit) for income taxes | 47 | 21 | 26 | ||||||
| Amortization and depreciation | 1,508 | 1,292 | 216 | ||||||
| EBITDA | $ | (43,984 | ) | $ | (35,498 | ) | $ | (8,486 | ) |
| Adjustments: | |||||||||
| Restructuring and impairment | 2,415 | 35 | 2,380 | ||||||
| Inventory write-down | 7,927 | - | 7,927 | ||||||
| Acquisition and transaction costs | 223 | - | 223 | ||||||
| Gain on change of warrant liability | (364 | ) | - | (364 | ) | ||||
| Loss on transfer of promissory note | 895 | - | 895 | ||||||
| Equity-based employee compensation expense | 2,231 | 5,434 | (3,203 | ) | |||||
| Adjusted EBITDA | $ | (30,657 | ) | $ | (30,029 | ) | $ | (628 | ) |
| Adjusted EBITDA loss per common share | (1.48 | ) | (2.34 | ) | 0.86 | ||||
| Weighted average common shares outstanding - basic and diluted | 20,711 | 12,856 | |||||||
Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA
Notes regarding Non-GAAP Financial Information
In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company provides EBITDA and Adjusted EBITDA.
In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.
The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.
| Last Trade: | US$0.77 |
| Daily Change: | 0.05 6.30 |
| Daily Volume: | 162,258 |
| Market Cap: | US$6.350M |
July 10, 2024 December 28, 2023 January 18, 2023 | |
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE